KN046 in Subjects With Advanced Solid Tumors and Lymphoma
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a phase Ia/Ib, open-label, multicenter, dose-escalation and expansion study to
evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN046 in
subjects with advanced solid tumors and lymphoma .